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Abstract 30 
Background and aims: Cross-sectional twin and family studies report a moderate 31 
heritability of baseline levels of C-reactive protein (CRP), ranging from 0.10 to 0.65 32 
for different age ranges. Here, we investigated the stability and relative impact of 33 
genetic and environmental factors underlying serum levels of CRP, using a 34 
longitudinal classical twin design. 35 
Methods: A maximum of 6,201 female twins from the TwinsUK registry with up to 36 
three CRP measurements (i.e. visit 1 [V1], visit 2 [V2] and visit 3 [V3]) over a 10-year 37 
follow-up period were included in this study. Structural equation modeling was 38 
applied to dissect the observed phenotypic variance into its genetic and environ-39 
mental components. To estimate the heritability of CRP as well as its genetic and 40 
environmental correlations across different time points, a trivariate model was used.  41 
Results: Natural log (ln) CRP levels significantly increased from V1 to V2 (p=4.4x10-42 
25) and between V1 and V3 (p=1.2x10-15), but not between V2 and V3. The median 43 
(IQR) follow-up time between V1 and V3 was 9.58 (8.00-10.46) years. Heritability 44 
estimates for CRP were around 50% and constant over time (0.46-0.52). Additionally, 45 
adjustment for BMI did not meaningfully change the heritability estimates (0.49–46 
0.51). The genetic correlations between visits were significantly smaller than one, 47 
ranging from 0.66 to 0.85.  48 
Conclusions: The present study provides evidence for stable heritability estimates of 49 
CRP of around 50% with advancing age. However, between-visit genetic correlations 50 
are significantly lower than 1, indicating emergence of new genetic effects on CRP 51 
levels with age. 52 
 53 
Keywords: aging, longitudinal, twins, heritability, C-reactive protein 54 
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Introduction 55 
The link between ageing and inflammation is well established. Low levels of microbial 56 
exposition early in life is known to promote the development of more competent 57 
immune pathways and regulatory processes. Such effective anti-inflammatory 58 
networks may counterbalance proinflammatory pathways (and CRP levels) activated 59 
by chronic diseases such as obesity and atherosclerosis [1]. Furthermore, ageing is 60 
known to be associated with a gradual dysregulation of inflammatory pathways 61 
resulting in an elevation of inflammatory factors [2–5]. It has been demonstrated that 62 
chronic low grade inflammation predisposes to many chronic, age-related diseases, 63 
such as those of the pulmonary and cardiovascular system [6–9]. We have 64 
previously demonstrated the role of age as a moderator of the genetic and 65 
environmental influences on baseline levels of inflammatory markers [10]. 66 
An important, well established inflammatory marker is C-reactive protein 67 
(CRP). Its baseline levels are considered to reflect systemic inflammation. 68 
Considering the relationship of increased baseline CRP levels with a variety of 69 
disorders, including cancer [11], bipolar disorder [12], cardiovascular diseases [13–70 
15], type 2 diabetes [16], and all-cause mortality [17], regulation of baseline CRP 71 
levels are of particular interest. In this context, baseline CRP levels have shown to be 72 
influenced by a variety of environmental and genetic factors. However, their relative 73 
importance and exact extent to which these factors account for the total variance in 74 
CRP level remain unknown [18].  75 
Heritability studies aim to estimate the relative influence of heritable and 76 
environmental factors on a trait [19]. Twin and family studies in a wide variety of 77 
populations with different age ranges showed a moderate heritability of baseline CRP 78 
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levels, with heritability estimates ranging from 0.10 to 0.65 [20–40] (Supplementary 79 
Table 3).  80 
CRP levels have been shown to be fairly stable over time. DeGoma et al. [41] 81 
analyzed serial CRP measures of 255 participants to evaluate the intraindividual 82 
variability of CRP over a median follow-up period of 4.7 years. The multivariable-83 
adjusted intraclass correlation coefficient (ICC) of CRP was estimated as 0.62. The 84 
intraindividual variability of CRP was also investigated by Wu et al. [42], using CRP 85 
levels of 56,218 Chinese adults over a two-year follow-up time. The ICC of CRP was 86 
reported as 0.55 for men and 0.60 for women. Interestingly, the stability of CRP 87 
gradually increased with age. However, twin and family studies mentioned above 88 
used single CRP measurement for their heritability calculation rather than longitudinal 89 
measurements. Limited by this cross-sectional design, heritability estimates for CRP 90 
as reported above only provide a snapshot at one particular point in time, potentially 91 
providing at least a partial explanation for the wide variety of heritability estimates 92 
reported in the literature [20–40]. 93 
To the best of our knowledge, no longitudinal twin studies on CRP levels have 94 
been conducted to date. The aim of this study was to evaluate the heritabilities and 95 
the extent to which genetic and environmental influences contribute to the stability or 96 
change of CRP over time in a large population of adult females using a classical twin 97 
design, including up to three CRP measurements over a ten-year follow-up period. 98 
 99 
Material and methods 100 
Subjects 101 
The study was conducted in 6,201 women from the Twins UK registry. Details of the 102 
Twins UK registry have been published before [43]. Zygosity was determined by 103 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
 
 
questionnaire supplemented by DNA fingerprinting in cases with disputed or 104 
uncertain zygosity. CRP measurement follow-up was performed up to 3 times, giving 105 
6,201 measurements in visit 1 (1,457 monozygotic (MZ) pairs, 1,584 dizygotic (DZ) 106 
pairs and 119 singletons), 2,251 measurements in visit 2 (452 MZ-pairs, 632 DZ-107 
pairs and 83 singletons) and 528 measurements in visit 3 (139 MZ-pairs, 112 DZ-108 
pairs and 26 singletons). 109 
 110 
C-reactive protein analysis 111 
High sensitive CRP was measured by latex-enhanced nephelometry on a Siemens 112 
(formally Behring) Prospec Nephelometer. The intra-assay precision expressed as 113 
coefficient of variation (CV) of this method is around 3.5% CV at 1.5 mg/l and 3.1% at 114 
12 mg/l and is expected to be <2% CV across the linear range of the assay. 115 
 116 
Analytical approach  117 
Natural log (ln) transformation was necessary for the CRP data to obtain a better 118 
approximation of the normal distribution. Secondly, lnCRP was adjusted for age. This 119 
is a common procedure in twin analyses because age can spuriously introduce a 120 
shared environmental effect if there is a significant correlation between the 121 
phenotype and age, because twins are always of the same age. Next, covariate 122 
analysis was performed, testing for: current smoking, body mass index (BMI), current 123 
oral contraceptive (OC) use and current hormone replacement therapy (HRT). It was 124 
our goal to test for a limited number of important covariates (i.e., age and BMI), 125 
rather than a more extensive list of potential covariates with more moderate effect 126 
sizes. This choice is unlikely to have biased our heritability estimates, because the 127 
potential effects of these covariates, in as far as they represent environmental 128 
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influences, will have ended up in the estimate of the Unique Environmental variance 129 
components E). No significant contribution to CRP variance was found for smoking, 130 
OC and HRT (p>0.05), the covariate models used were: 1) Age and 2) Age + BMI. 131 
That is, lnCRP was adjusted for age in model 1 and for both age and BMI in model 2 132 
after which the residuals were used in the model fitting. Models were fitted to the raw 133 
data using normal theory maximum likelihood allowing inclusion of incomplete data, 134 
for example, when data were only available in one twin of a pair or in a limited 135 
number of visits.  136 
Linear mixed model analysis was applied in longitudinal analyses to determine 137 
whether lnCRP differed between visits while accounting for both repeated 138 
measurements and twin relatedness by including the twin and family identification 139 
numbers as random effects in the model. Models with and without BMI as fixed effect 140 
were analyzed. The same approach was also used to test for differences in lnCRP 141 
levels between visits among those twins that returned for a second and/or a third 142 
visit. In simple cross-sectional analyses we used generalized estimating equations 143 
(GEE) to take account of the relatedness between twins. For example, to evaluate 144 
potential selective drop out over the different visits, we tested for the difference in 145 
age, BMI and lnCRP at baseline (i.e., visit 1) between twins that returned for a 146 
second or third visit and those that did not return using GEE. GEE was also used to 147 
test for differences in baseline characteristics between MZ and DZ twins. 148 
 149 
Model fitting  150 
Structural equation modeling (SEM) was the primary method of analysis. SEM is 151 
based on the comparison of the variance-covariance matrices in MZ and DZ twin 152 
pairs and allows separation of the observed phenotypic variance into its genetic and 153 
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environmental components: additive (A) or dominant (D) genetic components and 154 
common (C) or unique (E) environmental components, the latter also containing 155 
measurement error. The choice to start with either D or C in the full model depends 156 
on the relation between the MZ (rMZ) and DZ (rDZ) twin correlations. A D component 157 
is implied if 2xrDZ<rMZ whereas a C component is indicated if 2xrDZ>rMZ. Dividing 158 
each of these components by the total variance yields the different standardized 159 
components of variance. For example, the narrow sense heritability (h2) can be 160 
defined as the proportion of the total variance attributable to additive genetic variation 161 
[19].  162 
For the longitudinal analysis, a trivariate SEM or path model (also known as a 163 
Cholesky decomposition, Fig. 1) was used. With this model we can estimate both the 164 
heritability of CRP at different times of measurement separately, and also the genetic 165 
(rg) and environmental (re or rc) correlations between different time points, giving an 166 
estimation of the (in)stability of genetic and environmental influences with advancing 167 
age. We can further test whether the genes influencing CRP are the same (i.e. rg=1), 168 
partly the same (i.e. 0 < rg <1) or entirely different (i.e. rg=0) at different times of 169 
measurement (and therefore different ages). If they are partly the same, this bivariate 170 
model allows quantification of the amount of overlap between genes influencing CRP 171 
at different ages by calculating the genetic correlation between the traits: rg = COVA 172 
(trait 1, trait 2)/√(VAtrait1 * VAtrait2). 173 
Shared and unique environmental correlations can be calculated in a similar 174 
fashion [44,45]. In order to test for differences between twin 1 and twin 2, visits 1, 2 175 
and 3 and differences between MZ and DZ twins, we tested whether the means 176 
could be set equal between different twins (twin 1 and twin 2), time points (visit 1, 2 177 
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and 3) and zygosity groups (MZ and DZ) without a decline in model fit. A significant 178 
decline indicates that means cannot be assumed to be equal. 179 
 180 
Software 181 
All data handling and preliminary analyses were done with STATA (version 10.1, 182 
Statacorp, TX, USA). Quantitative genetic modeling was carried out using the Mx 183 
software package [46].  184 
Models were fitted to the raw data using normal theory maximum likelihood 185 
allowing inclusion of incomplete data, for example, when data were only available in 186 
one twin of a pair or in a limited number of visits. Using this method, Mx yields 187 
efficient maximum likelihood estimates even in the case of missing data through 188 
calculating twice the negative log-likelihood of the data for each observation (i.e. twin 189 
pair) [46]. This procedure follows the theory described by Lange et al., [47] based on 190 
the multivariate normal probability density function of a vector of observed scores. 191 
 192 
Results 193 
In Fig. 2, the distributions of lnCRP at the three visits for all twins combined are 194 
shown. lnCRP levels significantly increased from visit 1 (V1) to visit 2 (V2) (p=4.4x10-195 
25) and between V1 and visit 3 (V3) (p=1.2x10-15), but not between V2 and V3 196 
(p=0.69). Adjustment for BMI did not meaningfully change these results. The median 197 
(IQR) follow-up time was 5.60 (2.87-7.56) years between V1 and V2, 6.17 (4.10-7.53) 198 
between V2 and V3 and 9.58 (8.00-10.46) between V1 and V3. When limiting the 199 
analyses to individuals who returned for all 3 visits (robustness check), results were 200 
very similar. lnCRP levels among the 2,251 “returners” significantly increased in the 201 
interval between V1 and V2 (p=1.8x10-29), and between V1 and V3 (N= 528; 202 
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p=4.1x10-22), but not between V2 and V3 (N= 528; p=0.62) (Supplementary Figure 203 
1). Additionally adjusting lnCRP for BMI did not meaningfully change these results. 204 
 205 
Baseline characteristics of MZ and DZ twins for the three visits are 206 
summarized in Table 1. Significant differences between MZ and DZ twins exist for 207 
age (Visit 2 and 3, p<0.01), BMI (Visit 2, p<0.05) and lnCRP levels (Visit 1 and 2, 208 
p<0.05). In our twin models we corrected lnCRP for both age and BMI.  209 
Even though we optimally made use of the available follow-up measures of 210 
CRP over a ten year period, only subsamples of twins returned for the second and/or 211 
third visit. Those twins that returned for a second and/or third visit were not entirely 212 
representative of the whole sample as they were several years older, had lower BMIs 213 
and lower levels of CRP at baseline (details are given in Supplementary Table 2). 214 
Table 2 shows the intraclass twin correlations and results of the univariate 215 
SEM analysis of the two models for each of the three visits. For all three visits and 216 
both age adjusted, and age plus BMI adjusted lnCRP values MZ twin correlations 217 
were at least about twice as large as the DZ correlations clearly indicating the 218 
importance of genetic effects on lnCRP. In all models and visits, an AE-model was 219 
the best-fitting model. Heritabilities range from 0.46-0.52 (model 1) and 0.49-0.51 220 
(model 2). The heritabilities remain relatively stable over time and their confidence 221 
intervals overlap for all visits and models. 222 
 223 
Table 3 shows the results of the longitudinal trivariate analysis (Cholesky 224 
decomposition). We first tested effects of twin, visit and zygosity on the means. For 225 
model 1, mean values of twin 1 and twin 2 could be set equal within MZ and within 226 
DZ twins, but could not be set equal across visits and zygosity groups. For model 2, 227 
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in which CRP was adjusted for BMI, the means could additionally be set equal across 228 
all 3 visits, but remained different between MZ and DZ twins (see also Table 1). 229 
Since CRP levels between MZ and DZ twin pairs were different we allowed the 230 
means to remain different among zygosity groups in our statistical model to ensure 231 
that these differences could not bias the variance component. 232 
No evidence for a significant effect of genetic dominance was found as the AE 233 
model fitted best for both models. Heritability estimates for CRP were around 50% 234 
and very stable over time (0.50-0.53). Adjustment for BMI reduced heritabilities 235 
somewhat (0.45–0.49).  236 
The genetic correlations between first and second (respectively second and 237 
third) follow-up visits were 0.82 and 0.85 (model 1), and 0.78 and 0.77 (model 2). 238 
These correlations are large, but significantly smaller than 1, based on the non-239 
overlapping 95% CIs indicating the emergence of new genetic effects with age. 240 
When comparing the first with the third visit, the genetic correlation dropped (0.66 for 241 
model 1 and 0.55 for model 2), indicating increasingly different genetic effects with 242 
age. Environmental correlations between first and second (respectively second and 243 
third) follow-up visits were much smaller than the genetic correlations with estimates 244 
of 0.16 and 0.27 (model 1), and 0.15 and 0.26 (model 2). When comparing the first 245 
with the third visit, the correlation remained the same (0.19).  246 
As an additional sensitivity analysis we repeated the trivariate Cholesky 247 
modelling using only returning subjects, i.e., twins that participated in all three visits. 248 
Heritability estimates and genetic and environmental correlations showed similar 249 
results (Supplementary Table 1).  250 
 251 
 252 
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Discussion 253 
The present study assessed the stability of genetic and environmental influences 254 
underlying baseline CRP levels, using a longitudinal classical twin design, 255 
incorporating up to 3 follow-up measurements over a ten-year period. We were able 256 
to demonstrate relative stable heritabilities with advancing age of around 50%, which 257 
are in the same range as previous studies [20–40]. High genetic correlations of 0.66 258 
to 0.85 between visits indicate that genes influencing CRP levels are mostly the 259 
same at different ages, whereas low environmental correlations of 0.16 to 0.27 show 260 
that environmental factors are largely different between visits. Genetic correlations 261 
were significantly different from 1, however, also indicating emergence of some new 262 
genetic effects on CRP with age. 263 
 264 
The present study is, to our knowledge, the first to assess (and describe) the 265 
stability of genetic and environmental influences on baseline CRP levels in a 266 
longitudinal twin study. The longitudinal design, with the long follow-up time of up to 267 
10 years, and the relatively large sample size provided more statistical power and 268 
methodological opportunities compared to previous smaller, cross-sectional studies. 269 
We did not find evidence for genetic dominance, however, in contrast to some 270 
previous cross-sectional twin studies that also had large sample sizes [37,39].  271 
A limitation of the present study, however, is that our conclusions are not 272 
generalizable to men, or subjects with diseases since only data on relatively healthy 273 
women was assessed. The benefit of this homogenous sample, on the other hand, is 274 
that the results cannot be confounded by gender or disease since these covariates 275 
have previously been shown to have significant effects [48].  276 
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Even though we optimally made use of the available follow-up measures of 277 
CRP over a ten-year period, only subsamples of twins returned for the second and/or 278 
third visits. However, the Mx software package is capable of handling missing data 279 
by obtaining maximum likelihood estimates and takes advantage of including all 280 
available data rather than complete cases only [46]. Furthermore, a sensitivity 281 
analysis including only twins for which CRP data was available for all three visits 282 
yielded similar findings. As such, we believe it is unlikely that the differences between 283 
returning and non-returning twins will have translated into major biases in our model 284 
fitting parameter estimates. 285 
An interesting feature of our study, as mentioned above, is that we are the first 286 
to demonstrate relative stable heritabilities over time in a longitudinal design, even 287 
though the CRP levels itself do not seem stable (higher CRP-levels are described 288 
with advancing age) [2–5]. The present results show that the increase in CRP levels 289 
off between V2 and V3 and partial differences in gene repertoire may well be 290 
responsible for this. However, the aim of the present study was to describe stability 291 
and change of (co)variance patterns over time in terms of changes in underlying 292 
genetic and environmental variance components rather than explaining trends in 293 
mean-CRP-levels over time. As such, further biological explanations of this age trend 294 
in mean CRP remain speculative. 295 
           It has been hypothesized before that increased CRP levels with age may 296 
result from increases in “low grade, systemic, chronic inflammation” (due to 297 
atherosclerosis for example) [2–5]. Based on our previous findings [10], one may 298 
have expected an increasingly important role for random (i.e., unique environmental) 299 
components reflecting reduced homeostatic control with age in this process. 300 
However, this was not supported by our recent findings.   301 
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             The role of immunological pathways in somatic outcomes has well been 302 
established, as mentioned before in the introduction. This is, for example, illustrated 303 
by results on the role of microbial exposition in early life in the development of 304 
immune pathways and regulatory mechanisms [1], showing that a lack of exposition 305 
predisposes to “disrupted” immunological pathways and increased risk for allergic 306 
disorders. In this context, the relationship between Immunglobulin-E (IgE) and CRP 307 
would be of particular interest. This could be investigated in a multivariate twin study 308 
assessing the phenotypic and genetic relationship between IgE, CRP and age similar 309 
to our recent work on the relationship between neuroticism, CRP, fibrinogen, and IgG 310 
[49,50].  311 
 Genome-wide association studies (GWASs) have been able to identify several 312 
genomic loci associated  with serum levels of CRP. These studies have used large 313 
sample sizes of adult population, but have not  compared (possibly different) genomic 314 
effects on CRP levels with advancing age [51,52]. Our results, on the other 315 
hand,  indicate emergence of some new genetic effects on CRP with age and hence, 316 
warrants the need to repeat  large GWAS studies with stratifying the study population 317 
for different age ranges. Post-GWAS analyses  of the abovementioned CRP GWAS 318 
results revealed different biological processes involved in CRP  metabolism [53]. 319 
However, it is unclear whether these processes  are stable with advancing age. 320 
The present study provides evidence of a substantial role for genetics in the 321 
regulation of baseline CRP levels. Heritabilities are stable with advancing age, and 322 
(more interestingly) the impact of environmental components remains relatively 323 
stable too during the ten years our subjects were followed. Considering the genetic 324 
correlations were significantly smaller than 1 and reduced with follow-up time, genes 325 
regulating CRP levels at younger ages must be partly different from those at more 326 
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advanced ages. These results are in contrast with previous (cross-sectional) findings 327 
of other inflammatory markers, which indicate moderation of (changing) unique 328 
environmental factors with age in the regulation of IL-1β and TNF-α levels [10].  329 
In conclusion, this study emphasizes the relatively stable role of genetics in 330 
regulation of CRP levels, emphasizing its potential as a biomarker of ageing over 331 
other, more biologically reactive substances, in the various immunological pathways. 332 
Furthermore, the present study highlights the importance of a combination of both 333 
environmental factors and complex genetic pathways underlying the ageing process. 334 
Finally, even though the quantitative role of genetics in regulation of baseline CRP 335 
levels remained largely the same with age, the actual genes responsible for these 336 
effects were partly different at different ages. As such, future gene finding efforts 337 
need to take this into account, for example through investigating gene by age 338 
interaction effects.  339 
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Figure captions  584 
 585 
Figure 1. Path diagram for a bivariate model.  586 
For clarity, only one twin is depicted. A1, A2, A3 = Genetic variance components; C1, 587 
C2, C3 = common environmental variance components; E1, E2, E3 = unique 588 
environmental variance components; V1, V2, V3 = Visit 1, 2 and 3; a11 through a33 589 
= genetic path coefficients (or factor loadings); c11 through c33 = common 590 
environmental path coefficients (or factor loadings); e11 through e33 = unique 591 
environmental path coefficients (or factor loadings). 592 
 593 
Figure 2. Distributions of lnCRP at the three visits.  594 
An asterix means that there is a significant difference (p<0.05) in ln(CRP) between 595 
the respective visits. 596 
 597 
Supplementary figure 1 598 
Distributions of paired differences in lnCRP between two visits. An asterix means that 599 
the paired difference is significantly different from zero (p<0.05).  600 
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Table 1: General characteristics of twins by zygosity and visit number. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Differences between MZ and DZ twins were tested using GEE with adjustment for 
age (for BMI) and age and BMI (for CRP). CRP was transformed by natural logarithm 
prior to analysis.  
BMI, body Mass Index; CRP, C-reactive protein; DZ, dizygotic twins; MZ, 
monozygotic twins; N, number of subjects; ns, not significant.  
Data are given in mean±SD for age and BMI and median (IQR) for CRP.  
 
 MZ  DZ  p-value 
 N Age (years) N Age (years)  
      
Visit 1 2,955 49.1±13.4 3,246 48.3±12.4 ns 
Visit 2 934 57.9±10.1 1317 56.0±10.3 <0.01 
Visit 3 292 65.6±8.1 236 61.4±9.7  <0.01 
      
 N BMI (kg/m2) N BMI (kg/m2)  
Visit 1 2,955 25.4±4.6  3,246 25.6±4.7  ns 
Visit 2 934 25.7±4.2  1,317 26.3±4.8  <0.05 
Visit 3 292 26.1±4.2  236 26.3±4.4  ns 
      
 N CRP (mg/L) N CRP (mg/L)  
Visit 1 2,955 1.20 (0.48 – 3.15)  3,246 1.44 (0.58 – 3.47)  <0.05 
Visit 2 934 1.45 (0.68 – 3.39)  1,317 1.61 (0.72 – 3.89)  <0.05 
Visit 3 292 1.54 (0.73 – 3.18)  236 1.59 (0.73 – 3.80)  ns 
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Table 2: Intraclass correlations and parameter estimates of best fitting univariate models of lnCRP at the three visits.  
Visit Model Intraclass correlations Univariate Model Fitting 
  rMZ (95% CI) rDZ (95% CI)  A (95% CI) E (95% CI) 
1 N, pairs 1457 1584    
 1 0.54 (0.50-0.58)  0.24 (0.20-0.29)  AE 0.52 (0.46 – 0.58) 0.48 (0.42 – 0.54) 
 2 0.48 (0.44-0.52) 0.20 (0.16-0.25) AE 0.51 (0.38 – 0.61) 0.49 (0.39 – 0.62) 
2 N, pairs 452 632    
 1 0.50 (0.43-0.57)  0.25 (0.18-0.33)  AE 0.51 (0.45 – 0.57) 0.49 (0.43 – 0.55) 
 2 0.46 (0.38-0.53) 0.24 (0.17-0.31) AE 0.51 (0.39 – 0.62) 0.49 (0.38 – 0.61) 
3 N, pairs 139 112    
 1 0.54 (0.43-0.66) 0.13 (0.00-0.31)  AE 0.46 (0.40 – 0.52) 0.54 (0.48 – 0.60) 
 2 0.51 (0.39-0.64) 0.15 (0.00-0.33) AE 0.49 (0.36 – 0.59) 0.51 (0.41 – 0.64) 
Model 1, adjusted for age; Model 2, adjusted for age and BMI. 
 A, additive genetic variance component; E, unique environmental variance component. 
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Table 3: Parameter estimates (95% CI) of best fitting trivariate models of lnCRP 
levels. 
 
 
 
 
 
 
 
 
The best fitting model for all analyses was the AE model. 
 Genetic correlations [rg (95% CI)] are given below the diagonal and environmental 
correlations [re (95% CI)] above the diagonal; heritability [rg (95% CI)] estimates are 
given on the diagonal in bold, Model 1, adjusted for age; Model 2, adjusted for age 
and BMI. 
Model Visit 1 2 3 
1 1 0.53 (0.50-0.56) 0.16 (0.09-0.23) 0.19 (0.06–0.31) 
 2 0.82 (0.74-0.90) 0.50 (0.45-0.57) 0.27 (0.12-0.40) 
 3 0.66 (0.51-0.81) 0.85 (0.71-0.97) 0.52 (0.39-0.62) 
2 1 0.48 (0.44-0.51) 0.15 (0.08-0.22) 0.19 (0.06-0.31) 
 2 0.78 (0.70-0.87) 0.45 (0.40-0.52) 0.26 (0.12-0.39) 
 3 0.55 (0.40-0.70) 0.77 (0.61-0.92) 0.49 (0.36-0.59) 
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Highlights 
 
• Heritability estimates of C-reactive Protein (CRP) are around 50% and remain 
stable with advancing age. 
• Adjustment for body mass index did not change heritability estimates of CRP.  
• New genetic effects on CRP levels emerge with advancing age. 
